Top cited articles
Acceptance rate:
17%
Time to first decision with review:
27 days*
Acceptance to publication:
9 days*
Impact Factor (JCR):
19.103
Impact Factor rank (JCR):
2/34
Citescore:
28.5
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Smolen, Josef S; Landewe, Robert B. M; Bijlsma, Johannes W. J; et al
10.1136/annrheumdis-2019-216655
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco, Milena; Hyrich, Kimme L.; Al-Adely, Sarah; et al
10.1136/annrheumdis-2020-217871
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Furer, Victoria; Eviatar, Tali; Zisman, Devy; et al
10.1136/annrheumdis-2021-220647
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Strangfeld, Anja; Schafer, Martin; Gianfrancesco, Milena A; et al
10.1136/annrheumdis-2020-219498
Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017
Safiri, Saeid; Kolahi, Ali-Asghar; Smith, Emma; et al
10.1136/annrheumdis-2019-216515
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Hellmich, Bernhard; Agueda, Ana; Monti, Sara; et al
10.1136/annrheumdis-2019-215672
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Gossec, Laure; Baraliakos, Xenofon; Kerschbaumer, Andreas; et al
10.1136/annrheumdis-2020-217159
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
Geisen, Ulf M; Berner, Dennis K; Tran, Florian; et al
10.1136/annrheumdis-2021-220272
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis Fanouriakis, Antonis; Kostopoulou, Myrto; Cheema, Kim; et al
10.1136/annrheumdis-2020-216924
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
Haberman, Rebecca H; Herati, Ramin Sedaghat; Simon, David; et al
10.1136/annrheumdis-2021-220597
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
Furer, Victoria; Rondaan, Christien; Heijstek, Marloes W; et al
10.1136/annrheumdis-2019-215882
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression
Prendecki, Maria; Clarke, Candice; Edwards, Helena; et al
10.1136/annrheumdis-2021-220626
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
Braun-Moscovici, Yolanda; Kaplan, Marielle; Braun, Maya; et al
10.1136/annrheumdis-2021-220503
Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort
Pouletty, Marie; Borocco, Charlotte; Ouldali, Naim; et al
10.1136/annrheumdis-2020-217960
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
Simon, David; Tascilar, Koray; Fagni, Filippo; et al
10.1136/annrheumdis-2021-220461
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
Akiyama, Shintaro; Hamdeh, Shadi; Micic, Dejan;et al
10.1136/annrheumdis-2020-218946
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
Mrak, Daniel; Tobudic, Selma; Koblischke, Maximilian; et al
10.1136/annrheumdis-2021-220781
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases
Spiera, Robert; Jinich, Sarah; Jannat-Khah, Deanna
10.1136/annrheumdis-2021-220604
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
Boyarsky, Brian J; Ruddy, Jake A; Connolly, Caoilfhionn M; et al
10.1136/annrheumdis-2021-220289
EULAR recommendations for the management of Sjogren’s syndrome with topical and systemic therapies
Ramos-Casals, Manuel; Brito-Zeron, Pilar; Bombardieri, Stefano; et al
10.1136/annrheumdis-2019-216114